

1 Direct RNA nanopore sequencing of SARS-CoV-2 extracted 2 from critical material from swabs

3
4 **Davide Vacca^{at}, Antonino Fiannaca^{bt}, Fabio Tramuto^a, Valeria Cancila^a, Laura La Paglia^b,
5 Walter Mazzucco^a, Alessandro Gulino^c, Massimo La Rosa^b, Carmelo Massimo Maida^a,
6 Gaia Morello^a, Beatrice Belmonte^a, Alessandra Casuccio^a, Rosario Maugeri^d, Gerardo
7 Iacopino^d, Francesco Vitale^{as}, Claudio Tripodo^{as}, Alfonso Urso^{bs}**

8
9 ^a University of Palermo, Department of Sciences for Health Promotion and Mother-Child Care
10 “G. D’Alessandro”, Piazza delle cliniche N°2, zip code 90127, Palermo, Italy.

11
12 ^b CNR-ICAR, National Research Council of Italy, Via Ugo La Malfa, a5c, Palermo, Italy.

13
14 ^c Cogentech srl Società Benefit, FIRC Institute of Molecular Oncology (IFOM)
15 Via Adamello 16, 20139, Milan, Italy

16
17 ^d Department of Experimental Biomedicine and Clinical Neurosciences, School of Medicine,
18 Neurosurgical Clinic, University of Palermo, Palermo, Italy.

19
20 [†] Equal contributors.

21 [§] Equal contributors

22 23 **ABSTRACT**

24 **Background.** In consideration of the increasing prevalence of COVID-19 cases in
25 several countries and the resulting demand for unbiased sequencing approaches, we
26 performed a direct RNA sequencing experiment using critical oropharyngeal swab
27 samples collected from Italian patients infected with SARS-CoV-2 from the Palermo
28 region in Sicily.

29 **Methods.** Here, we identified the sequences SARS-CoV-2 directly in RNA extracted
30 from critical samples using the Oxford Nanopore MinION technology without prior cDNA
31 retro-transcription.

32 **Results.** Using an appropriate bioinformatics pipeline, we could identify mutations in the
33 nucleocapsid (N) gene, which have been reported previously in studies conducted in
34 other countries.

35 **Conclusion.** To the best of our knowledge, the technique used in this study has not
36 been used for SARS-CoV-2 detection previously owing to the difficulties in the
37 extraction of RNA of sufficient quantity and quality from routine oropharyngeal swabs.

38 Despite these limitations, this approach provides the advantages of true native RNA
39 sequencing, and does not include amplification steps that could introduce systematic
40 errors.

41 This study can provide novel information relevant to the current strategies adopted in
42 SARS-CoV-2 next-generation sequencing.

43 We deposited the gene sequence in the NCBI database under the following
44 URL:<https://www.ncbi.nlm.nih.gov/nucleotide/MT457389>

45

46 **KEYWORDS** MinION, Direct RNA Nanopore sequencing, Sars-CoV-2, Covid19, Swab

47

48 **INTRODUCTION**

49 The study of the SARS-CoV-2 genome has become a priority for global healthcare to
50 facilitate the identification of more suitable vaccines and therapeutic drugs (1).

51 The use of third generation sequencing technologies has increased significantly in
52 recent years, as these methods yield reliably long reads even from biological samples
53 with noise (2).

54 Direct RNA sequencing (RNA-seq) of SARS-CoV-2 has the advantage of displaying its
55 native sequence without contamination by artefacts originating from the in vitro cDNA
56 amplification step, which is often necessary for target enrichment (3). However, the
57 quality of RNA extracted from the swab has certain critical issues with respect to both
58 fragmentation level and concentration, such that the read coverage of sequencing
59 decreases considerably. In this study, we investigate the suitability of Nanopore Oxford
60 MinION Mk1B (4), a third-generation nanopore-based platform, for the identification of a
61 critical target of SARS-CoV-2 native RNA from a swab sample, and its sensitivity in the
62 characterization of the viral mutational landscape.

63 To this end, we analyzed ten RNA samples extracted from oropharyngeal swabs of ten
64 patients with COVID-19, and sequenced them in two pools following the direct RNA
65 sequencing protocol (SQK-RNA002, Nanopore Technologies). Although the
66 concentration of the library loaded in the sequencing flow cell was approximately 200
67 times lower than that required for the protocol, we clearly identified two mutations in the
68 nucleocapsid phosphoprotein (N) gene with respect to the sequence of the strain
69 isolated in Wuhan, which has been described in literature.

70

71 **MATERIALS AND METHODS**

72 After the collection of ten oropharyngeal swab samples from Italian patients with
73 COVID-19, we assayed the concentration and fragmentation level of the extracted RNA
74 to arrange it for sequencing, as recommended by Oxford Nanopore in the Input
75 DNA/RNA quality control guidelines (5). Next, we prepared two sequencing libraries
76 from two distinct pools, as described below, and launched a computational pipeline for

77 aligning the obtained reads. Lastly, we confirmed the mutation frequency in our sample
78 either by Sanger sequencing or by real-time PCR (qPCR) assays.

79

80 **Input RNA collection and quality control steps**

81

82 **Samples.** For this study, we collected RNA samples from ten Sicilian patients between
83 March 19th and 23rd, 2020. The patients tested positive in the 2019-Novel Coronavirus
84 (2019-nCoV) Real-time rRT-PCR Panel (Centers for Disease Control and Prevention
85 (CDC) Atlanta, GA 30333).

86 Furthermore, to compare the nanopore sequencing results, we included two samples
87 from uninfected individuals as negative controls. The RNA from uninfected controls was
88 extracted from brain biopsy specimens of two patients who underwent surgery in August
89 2019 and in January 2020, respectively. Both biopsies were made available from
90 Department of Experimental Biomedicine and Clinical Neurosciences, School of
91 Medicine, Neurosurgical Clinic, University of Palermo.

92

93 **RNA extraction.** The swab buffer kit was assayed using the QIAamp Viral RNA Mini Kit
94 in Automated purification of RNA on QIAcube Instruments (Qiagen, Cat.No 9001292)
95 according to the manufacturer's instructions.

96

97 **Assessment of concentration and fragmentation level.** The quality of the
98 fragmented sample was assessed with an Agilent Bioanalyzer 2100 (Agilent, Cat.No
99 G2939BA) using the Agilent RNA 6000 Pico assay (Agilent, Cat.No 5067-1513). We
100 assayed 1 μ L of each pure sample. The RNA extracted from the samples showed high
101 fragmentation and lowest concentration levels with an RIN index between 2.6 and 2.1
102 and concentration between 19 and 829 $\text{pg}/\mu\text{L}$.

103

104 **Preparation of the libraries and the computational pipeline**

105 The samples were organized in two pools (A and B), each with a final volume of 10 μL .
106 Pool A included samples from three patients: two with a PCR cycle threshold (Ct) value
107 of 18 and one with Ct value of 20. To elaborate, we pooled 8 μL of samples from the
108 first two patients (4 μL from each) and 2 μL from the last patient.

109 Pool B included RNA samples collected from ten patients (1 μL from each patient):
110 three samples were from pool A, while the other seven had decreasing Ct values, and
111 were collected from two patients with Ct value of 21, two with 22, two with 23, and one
112 with 24.

113 **Library preparation, priming, and commencement of a sequencing run.** Both pools
114 were sequenced using a MinION Mk1B sequencer with the SQK-RNA002 protocol.

115 After preparing the sequencing libraries A and B, as previously described, to ligate
116 retro-transcription adapters (RTA) to the 3'-end of the RNA molecules, we combined
117 each library with 6 μL of a mix comprising 3 μL of NebNext Quick Ligation Reaction
118 Buffer, 1.5 μL of T4 DNA Ligase, 1 μL of RTA, and 0.5 μL of 110 nM RNA CS (RCS).
119 Each reaction was incubated for 10 min at 22 $^{\circ}\text{C}$. Next, the reactants were mixed with 9
120 μL of nuclease-free water, 8 μL of 5X first-strand buffer, 4 μL of 0.1 DTT, and 2 μL of 10
121 mM dNTPs. For cDNA synthesis, we added 2 μL of SuperScript III, following which both
122 reactions were incubated under the following conditions: 50 $^{\circ}\text{C}$ for 50 min, 70 $^{\circ}\text{C}$ for 10
123 min, and 4 $^{\circ}\text{C}$ before proceeding to the next step.

124 The subsequent wash step was performed according to the procedure for the specified
125 protocol.

126 Next, we measured the concentration of 1 μL of each library using a Qubit 3.0
127 Fluorimeter and the dsDNA HS assay kit (Life Technologies, Cat. No Q32851). The
128 concentrations were 1.2 ng/ μL and 0.6 ng/ μL for libraries A and B, respectively.

129 Next, we performed the Attachment of 1D sequencing adapter step according to
130 manufacturer instructions, and recorded final concentrations of 0.9 ng/ μL and 0.3 ng/ μL
131 for A and B, respectively.

132 Lastly, 20 μL of sample from each library was mixed with 17.5 μL of nuclease-free water
133 and 37.5 μL of RNA running buffer (RRB) in a final volume of 75 μL .

134 The assessment of the R9.4 Flow Cell, which was performed prior to the loading of the
135 libraries, revealed that 1575 active pores were available for sequencing.

136 We performed a new MinKNOW (6) (*v19.12.5*) experiment using only the A loading mix
137 in the flow cell.

138 In MinKNOW we selected the SQK-RNA002 Kit and continued the sequencing process
139 until approximately 80% pores were available (i.e., after 4 h). At this point, we paused
140 the process and loaded the B loading mix in the flow cell. Next, the run was resumed
141 and continued till the number of reads generated was unvaried at 397k (i.e., after
142 approximately 27 h). At the end of the sequencing process, we obtained the "Fast5" raw
143 data files.

144

145 **Computational pipeline.** We developed a computational pipeline to analyze the output
146 from the Oxford Nanopore MinION device. The first step in the process involved the
147 conversion of "Fast5" in "Fastq" format. For this, we used the GPU version of the
148 Nanopore *Guppy* basecaller (*v3.4.4*) tool (7) with the following parameters: "*flow_cell =*
149 *FLO-MIN106*" and "*kit = SQK-RNA002*".

150 As a second step, we performed read quality control using the *PycoQC* (*v2.5.0.21*)
151 software (8) with standard parameters. This tool computes metrics and generates
152 multiple quality plots for Nanopore technologies that allow the initial evaluation of the
153 sequenced reads.

154 *PycoQC* can subsequently provide an overview of the overall quality of the reads. To
155 clean the input data, we filtered the quality and read length using the *NanoFilt (v2.7.0)*
156 tool (9). This tool can also analyze the sequencing summary file generated by
157 *guppy_basecaller* to refine the filtering process. For these reasons, we filtered the reads
158 using the sequencing summary file under the following parameters: minimum read
159 length ≥ 500 nt and read quality ≥ 8 .

160 Thereafter, only the filtered reads were considered in further analysis.

161 At this point, we created an alignment process that mapped reads to a reference
162 genome and identified the exact genomic loci corresponding to each read. Given that,
163 we did not use primers for the amplification of the SARS-CoV-2 genome, we had to
164 remove all the reads that were mapped with other material sequenced from the swabs.
165 In this study, to remove the contaminating sequences, we considered humans, fungal,
166 and bacterial reference genomes, respectively. To elaborate, we used the "Homo
167 sapiens genome assembly *GRCh38 (hg38)*" from the Genome Reference Consortium
168 (10) as the human reference genome, and all sequences from both fungal and bacterial
169 genome projects from NCBI (11). Lastly, we used the NCBI SARS-CoV-2 sequence
170 NC_045512.2 (12) as a reference genome for SARS-CoV-2.

171 For each of these reference genomes, we mapped the reads using the *minimap2*
172 (*v2.17-r941*) tool (13) based on earlier reports that demonstrated the effective
173 performance of this tool with the splice-aware alignment of Nanopore Direct RNA reads
174 against a reference genome (14). As suggested by authors who reported the
175 performance of *minimap2*, we set the parameter $k = 13$ to increase the sensitivity and to
176 map noisy Nanopore Direct RNA-seq reads.

177 Next, we extracted both unmapped reads and reads with mapping quality lower than 10
178 using the "view" utility in the *samtools (v1.7)* library (15) for each reference genome
179 except for that of SARS-CoV-2.

180 Resultantly, we obtained a sub-set of the sequenced long-reads that did not map with
181 the genomes of human, fungi, or bacteria.

182 Lastly, we mapped the remaining reads against the SARS-CoV-2 reference genome
183 using *minimap2* tools with the same parameters used earlier. We successively analyzed
184 the results of the mapping process using the *BCFtools (v1.9)* library (16), a set of
185 utilities for variant calling. In particular, we first used the *mpileup* tool (16) to generate a
186 summary of the coverage of the mapped reads on the SARS-CoV-2 reference genome
187 at single base-pair resolution, followed by the *call* tool (17) for generating calls. We set
188 these tools to perform as the standard consensus-caller with only the variant sites
189 returned. The results of this pipeline were enlisted as SARS-CoV-2 variants detected in
190 the sequenced samples from the swabs.

191

192

193 **Calculation of mutation frequency**

194

195 **Sanger sequencing.** The samples were sequenced using the BigDye™ Terminator
196 v3.1 Cycle Sequencing Kit (Life Technologies; Cat no 4337455) with an ABI PRISM
197 3100 Genetic Analyzer upgraded to the Applied Biosystems® 3130xl System (Life
198 Technologies; Cat no 4359571). To enrich the identified mutation region in the N gene,
199 we adopted a nested PCR approach using an outer and an inner primer sets. Both
200 primer sets are reported in Tab. S1.

201

202 **RT-PCR.** The ten sequenced samples and the two uninfected control RNAs were retro-
203 transcribed using the EcxcelRT™ Reverse Transcription kit (SMOBIO, Cat. No RP1300).
204 First, 16 µL of each sample was mixed with 2 µL of 50 µM of Oligo (dT)₂₀ primer and 2
205 µL of dNTP Mix (10 mM each). The mixes were incubated at 70 °C for 5 min and placed
206 on ice for at least 1 min. Next, 8 µL of 5X RT Buffer (DTT), 8 µL of DEPC-Treated water,
207 2 µL of RNAok™ Rnase Inhibitor, and 2 µL ExcelRT™ Reverse Transcriptase was
208 added to each sample. The reactions were incubated at 25 °C for 10 min, at 44 °C for
209 50 min, and at 85 °C for 5 min, and were subsequently held at 4 °C.

210

211 **qPCR.** To amplify the region containing the NC_045512:c.608_609_610delinsAAC
212 mutation, we designed two primer sets to distinguish between a wild type (WT) and a
213 mutated viral strain. The two sets used the same reverse primer, with divergence at the
214 last three bases at the 3'-end of the forward primer. In fact, one forward primer was
215 specific for the mutated sequence, whereas the other recognized the reference
216 sequence.

217 We used two other sets as controls. One set consisted of the primers N2 from the 2019-
218 Novel Coronavirus (2019-nCoV) Real-time rRT-PCR Panel (Centers for Disease Control
219 and Prevention (CDC) Atlanta, GA 30333), which was used to confirm the presence of
220 the N gene target (Fig. S1 and Tab. S2). The second set consisted of a custom specific
221 primer for human *GAPDH* cDNA, which was used as an endogen control for the PCR
222 (Fig. S2 and Tab. S3). All primer sequences are listed in Tab. S1.

223 Moreover, a plasmid vector carrying a synthetic reference SARS-CoV-2 N gene
224 (Origene, Cat No: VC202563) was used as a reference control.

225 First, both analysis samples and uninfected control cDNA samples were diluted at a 1:2
226 ratio, while the reference control was concentrated to 0.8 ng/µL. Next, 4 µL of each
227 sample in 20 µL of reaction mixture was assayed by qPCR using the Quantinova SYBR
228 Green PCR kit (Qiagen, Cat No.: 208052) according to the manufacturer's instructions
229 in a Rotor-Gene Q 5plex HRM Thermocycler (Qiagen, Cat No./ID: 9001580). The
230 following PCR thermal profile was used: 95 °C, 2 min; 95 °C, 5 s and 57 °C, 10 s for 35
231 cycles.

232

233

234 RESULTS

235 To characterize the SARS-CoV-2 mutational landscape, we used RNA extracted from
236 samples collected from five male and five female patients who tested positive for SARS-
237 CoV-2 in the swab-test, with the corresponding Ct values ranging from 18 to 24. First,
238 we assessed the concentrations and the fragmentation levels in the samples, as
239 reported in the Materials and Methods. The overall samples had significantly low
240 concentrations (in the order of pg/ μ L) and high fragmentation levels with an RIN index
241 ranging from 2.6 to 2.1. Next, we prepared the pools A and B from the samples, as
242 explained in the Materials and Methods. We prepared the former to increase the
243 abundance of sequencing output and the latter to improve the heterogeneity in the data.
244 We set up each pool at a final volume of 10 μ L, and prepared the libraries for direct
245 RNA-seq, as described in the Materials and Methods.

246 After each purification step, the concentrations were 1.2 ng/ μ L and 0.6 ng/ μ L in the
247 initial eluates, and 0.9 ng/ μ L and 0.3 ng/ μ L in the final eluates at the pre-sequencing
248 stage for pools A and B, respectively.

249 Although the library concentrations were 200 times less than that required for the
250 protocol, we opted to load the libraries and test the suitability of MinION.


251 To perform a single MinION sequencing run, we loaded library A in the flow cell at the
252 beginning of the run with 1,575 active pores enabled, while library B was loaded when
253 1,260 active pores remained active, as described in the Materials and Methods.

254 Using the *MinKNOW* and *Guppy* basecaller tools, we obtained a set of 397,465 reads in
255 the Fastq format file.

256 As we stated previously, the overall quality of reads is affected by the adopted
257 sequencing technique; i.e., the direct RNA sequencing of samples derived from the
258 swabs. In this experiment, the average read length was lower than that of standard
259 long-reads, and the quality of certain reads was below conventional levels. Therefore,
260 we preferred to discard the reads that had low quality (< 8) as well as a short length ($<$
261 500 nt). We obtained a subset of 20,940 good-quality reads.

262 At this point, we aimed to identify and remove sequences from contaminant species
263 contained in the swab; for this, we used the *minimap2* tool (13) to filter out reads that
264 mapped with sequences from human, fungal, and bacterial genomes.

265 Using this method, we filtered 97.63% of the reads; details of the composition of these
266 reads are provided in Tab. S4. Lastly, we attempted to map the remaining 2.37% of
267 reads with the SARS-CoV-2 reference genome, and observed that 10.89% of the reads
268 (i.e., 54 reads) mapped. These reads did not cover the entire SARS-CoV-2 reference
269 genome; however, these were sufficient for mapping the N gene.



292
293 **Fig. 2** The sequences obtained by Sanger sequencing of RNA extracted from swabs
294 who tested positive for SARS-CoV-2 infection. The rectangle covers coordinates from
295 28881 to 28883 for underlines as all samples contained the
296 NC_045512:c.28881_28882_28883delinsAAC mutation.
297

298 In the qPCR assay, we used custom primer sets designed to distinguish between WT
299 and mutated sequences, and another pair set, as reported in the Materials and
300 Methods. We compared two uninfected controls and the synthetic SARS-CoV-2 N
301 cDNA, which was similar to the reference control. All the samples yielded positive
302 results with the primer set specified for the mutated sequence (Fig. S3 and Tab. S5)
303 and negative for the WT sequence (Fig. S4 and Tab. S6), in contrast to that for the
304 reference control, consistent with the results of the Sanger sequencing experiment. The
305 uninfected samples tested negative for both mutated and WT sets, which confirmed the
306 absence of a possible off-target from the host.
307

308 DISCUSSION

309 Next-generation sequencing technologies can be used to detect the nucleotide
310 sequences in analyzed samples within a short duration and at an affordable cost (18).
311 However, these approaches depend on both the harvest and extraction protocols of the
312 sample, which significantly influence the coverage and depth of the sequencing reads
313 (21, 22).


314 Even though cDNA sequencing is considered the gold standard for the analysis of
315 critical materials (23), DNA polymerase can introduce certain read errors during the
316 DNA synthesis step, which can considerably affect the SNPs analysis (3, 22).

317 Instead, direct RNA-seq can help identify the native sequences without contamination
318 by artefacts that are usually introduced in the in vitro amplification step, even though it
319 requires a higher input concentration compared to cDNA sequencing methods (21)

320 In this context, swab RNA, which has a lower concentration and is also more
321 fragmented than in vitro RNA, may not be suitable for performing direct sequencing.

322 However, the performance of the MinION flow cell has improved exponentially in recent
323 years (2); therefore, we chose to utilize MinION Mk1B to characterize the mutational
324 landscape in the critical samples.

325 To maintain the sequencing input concentration and its heterogeneity, we combined
326 RNA samples from two pools (A and B). At the end of the library workflow, both samples
327 were present at concentrations that were approximately 200 times less than that
328 required for the protocol. In fact, owing to insufficient starting material, we observed that
329 only a limited number of pores were active at a time, as shown in the MinKNOW duty
330 time plot in Fig. 3.





331
332 **Fig. 3** The MinKNOW duty time plots depict the sum of total channel activity within a
333 particular period of time. The number of sequencing pores decrease over time. In the
334 categorized plot, the imbalance of adapters is apparent.

335
336 Resultantly, we only obtained a few reads (approximately 0.3%), which showed
337 significant variant calling. Next, we investigated whether findings from other studies on
338 SARS-CoV-2 were consistent with our findings. To this end, we considered sequence
339 variations from the China National Center for Bioinformatics (CNGB) portal (23). CNGB
340 is the largest, daily-updated, publicly available SARS-CoV-2 genome variation
341 repository. It contains more than 21,000 high-quality, human-hosted, complete SARS-
342 CoV-2 genomes (last download on 12-Jun-2020) from several countries worldwide. We

343 retrieved this dataset and prepared a script to check for the presence of the identified
344 mutation region (NC_045512:c.28881_28882_28883delinsAAC) in the sequences of N
345 gene present in CNCB's dataset. As shown in Fig. 4A, we considered three sets: 1)
346 cases that only contained identified mutations, 2) cases that also contained identified
347 mutations, and 3) cases that did not contain the identified mutations. We found that the
348 same N gene sequence reported by us was reported in approximately 18% of COVID-
349 19 cases, and we took into account the distribution of these cases over time.
350 As shown in Fig. 4B, we reported the presence of the mutation in cases treated per
351 week from February to June, and noticed that the majority of cases were reported
352 between the second week of March and the fourth week of April. This period coincided
353 with that of swab collection from patients.

A Distribution of the reported mutation in CNCB



354 **Fig. 4** Identification of the reported mutation in the CNCB database. (A) Strains
355 isolated from 18.3% of COVID-19 cases (over 21,000 complete genomes sequenced
356 from isolated strains) contained the reported mutation. (B) Plot depicting the
357 distribution of these cases from the end of February to the beginning of June.
358
359

360 Lastly, we wanted to compare the in silico results using Sanger sequencing and qPCR
361 techniques, as described in the Results section. The presence of the
362 NC_045512:c.28881_28882_28883delinsAAC mutation was confirmed using both
363 methods in all the samples used in this study. Our results validated the approach of
364 direct RNA-seq with Oxford Nanopore MinION technology. Additionally, the presence of

365 molecular targets for the identification of specific genomic mutations was confirmed, and
366 could be considered advantageous for both surveillance and epidemiologic studies.

367

368 **Data availability**

369 The data that support the findings of this study are available from the corresponding
370 author upon reasonable request.

371 Supplemental material is available to link:

372 [https://www.dropbox.com/sh/yphu9kzd64mnrI7/AAC8khoPjZ8wSeZRk_6DFd6a?dl=](https://www.dropbox.com/sh/yphu9kzd64mnrI7/AAC8khoPjZ8wSeZRk_6DFd6a?dl=0)
373 0

374

375 **Contributions**

376 DV: Data curation, Formal analysis, Methodology, Software, Writing, Editing; AF: Data
377 curation, Formal analysis, Methodology, Software, Writing, Editing; FT: Investigation,
378 Methodology, Resources, Visualization; VC: Investigation, Methodology, Visualization;
379 LLP: Visualization, Review, Editing; WM: Investigation, Resources, Visualization; AG:
380 Data curation, Visualization; MLR: Data curation, Methodology, Visualization, Review,
381 Editing; CM: Data curation, Methodology, Resources, Visualization; GM: Data curation,
382 Methodology, Visualization; BB: Data curation, Visualization; AC: Data curation,
383 Investigation, Resources, Visualization; RM: Resources, Visualization; GI: Resources,
384 Visualization; FV: Conceptualization, Data curation, Investigation, Supervision,
385 Visualization, Writing, Review, Editing; CT: Conceptualization, Data curation, Funding
386 acquisition, Investigation, Project administration, Supervision, Visualization, Writing,
387 Review, Editing; AU: Conceptualization, Data curation, Investigation, Supervision,
388 Visualization, Writing, Review, Editing

389

390 **Conflicts of interest.**

391 All authors no reported conflicts.

392

393 **REFERENCES**

- 394 1. Bafna K, Krug RM, Montelione GT. Structural Similarity of SARS-CoV2 Mpro and HCV
395 NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as
396 COVID-19 Therapeutics. Preprint. ChemRxiv. 2020;10.26434/chemrxiv.12153615.v1.
397 Published 2020 Apr 21. doi:10.26434/chemrxiv.12153615
- 398 2. Kono N, Arakawa K. Nanopore sequencing: Review of potential applications in functional
399 genomics. Dev Growth Differ. 2019;61(5):316-326. doi:10.1111/dgd.12608
- 400 3. Brandariz-Fontes C, Camacho-Sanchez M, Vilà C, Vega-Pla JL, Rico C, Leonard JA. Effect
401 of the enzyme and PCR conditions on the quality of high-throughput DNA sequencing
402 results. Sci Rep. 2015;5:8056. Published 2015 Jan 27. doi:10.1038/srep08056; Depledge

- 403 DP, Wilson AC. Using Direct RNA Nanopore Sequencing to Deconvolute Viral
404 Transcriptomes. *Curr Protoc Microbiol.* 2020;57(1):e99. doi:10.1002/cpmc.99
- 405 4. Oxford Nanopore Technologies, Nanopore Oxford MinION 1kb,
406 https://community.nanoporetech.com/requirements_documents/minion-it-reqs.pdf
- 407 5. Oxford Nanopore Technologies, Input DNA/RNA QN,
408 <https://community.nanoporetech.com/protocols/input-dna-rna->
409 [qc/v/IDI_S1006_v1_revB_18Apr2016](https://community.nanoporetech.com/protocols/input-dna-rna-)
410 https://community.nanoporetech.com/technical_documents/minknow-tech-
411 [doc/v/mitd_5000_v1_revaa_16may2016](https://community.nanoporetech.com/technical_documents/minknow-tech-)
- 412 6. Oxford Nanopore Technologies, Guppy basecaller tool (2020), <https://nanoporetech.com/>
- 413 7. Leger A, Leonardi T, pycoQC, interactive quality control for Oxford Nanopore Sequencing.
414 *Journal of Open Source Software* (2019), 4(34), 1236, <https://doi.org/10.21105/joss.01236>
- 415 8. Wouter De Coster, Sven D'Hert, Darrin T Schultz, Marc Cruys, Christine Van Broeckhoven,
416 NanoPack: visualizing and processing long-read sequencing data, *Bioinformatics*, Volume
417 34, Issue 15, 01 August 2018, Pages 2666–2669,
418 <https://doi.org/10.1093/bioinformatics/bty149>
- 419 9. Schneider VA, Graves-Lindsay T, Howe Kerstin et al., Evaluation of GRCh38 and de novo
420 haploid genome assemblies demonstrates the enduring quality of the reference assembly,
421 *bioRxiv* (2016), Cold Spring Harbor Laboratory, <https://doi.org/10.1101/072116>
- 422 10. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology
423 Information, (1988) [cited 2020 Jun 28]. Available from: <https://www.ncbi.nlm.nih.gov/>
- 424 11. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology
425 Information, (1988), Accession No. NC_045512.2, Severe acute respiratory syndrome
426 coronavirus 2 isolate Wuhan-Hu-1, complete genome; [cited 2020 Jun 28]. Available from:
427 https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2/
- 428 12. Li H, Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* (2018), 34,
429 3094-3100.
- 430 13. Lin, H., Hsu, W. GSAalign: an efficient sequence alignment tool for intra-species genomes.
431 *BMC Genomics* 21, 182 (2020). <https://doi.org/10.1186/s12864-020-6569-1>
- 432 14. Li H, Handsaker B, Wysoker A, et al. 1000 Genome Project Data Processing Subgroup, The
433 Sequence alignment/map (SAM) format and SAMtools, *Bioinformatics* (2009) 25(16) 2078-9
- 434 15. Li H, A statistical framework for SNP calling, mutation discovery, association mapping and
435 population genetical parameter estimation from sequencing data, *Bioinformatics* (2011)
436 27(21) 2987-2993.
- 437 16. James T. Robinson, Helga Thorvaldsdóttir, Aaron M. Wenger, Ahmet Zehir, Jill P. Mesirov.
438 Variant Review with the Integrative Genomics Viewer (IGV). *Cancer Research* (2017),
439 77(21) 31-34.
- 440 17. Vacca D, Cancila V, Gulino A, et al. Real-time detection of BRAF V600E mutation from
441 archival hairy cell leukemia FFPE tissue by nanopore sequencing. *Mol Biol Rep.*
442 2018;45(1):1-7. doi:10.1007/s11033-017-4133-0

- 443 18. Trost B, Walker S, Haider SA, et al. Impact of DNA source on genetic variant detection from
444 human whole-genome sequencing data. *J Med Genet.* 2019;56(12):809-817.
445 doi:10.1136/jmedgenet-2019-106281
- 446 19. Zhu Q, Hu Q, Shepherd L, et al. The impact of DNA input amount and DNA source on the
447 performance of whole-exome sequencing in cancer epidemiology. *Cancer Epidemiol*
448 *Biomarkers Prev.* 2015;24(8):1207-1213. doi:10.1158/1055-9965.EPI-15-0205
- 449 20. Shanker S, Paulson A, Edenberg HJ, et al. Evaluation of commercially available RNA
450 amplification kits for RNA sequencing using very low input amounts of total RNA. *J Biomol*
451 *Tech.* 2015;26(1):4-18. doi:10.7171/jbt.15-2601-001
- 452 21. Depledge DP, Wilson AC. Using Direct RNA Nanopore Sequencing to Deconvolute Viral
453 Transcriptomes. *Curr Protoc Microbiol.* 2020;57(1):e99. doi:10.1002/cpmc.99
- 454 22. Zhao WM, Song SH, Chen ML, et al. The 2019 novel coronavirus resource. *Yi Chuan.*
455 2020;42(2):212–221. doi:10.16288/j.ycz.20-030